Predictive Impact of Tumor Mutational Burden on Real-World Outcomes of First-Line Immune Checkpoint Inhibition in Metastatic Melanoma

Predictive Impact of Tumor Mutational Burden on Real-World Outcomes of First-Line Immune Checkpoint Inhibition in Metastatic Melanoma

Medicine, Oncology,
tumor mutational burden   immune checkpoint inhibition   metastatic melanoma   real-world study   biomarkers   efficacy prediction   BRAF status  

Study on Real-world Outcomes of First-line Immune Checkpoint Inhibitor Therapy in Metastatic Melanoma Predicted by Tumor Mutational Burden The treatment of metastatic melanoma has significantly benefited from immune checkpoint inhibitors (ICIs) in recent years. However, despite the remarkable improvement in survival rates among melanoma patients, t...